Treatment shows potential to slow the progression of human degenerative eye diseases, including retinitis pigmentosa.

Mount Sinai scientists will continue studying PGV001 in larger groups of patients and testing how it works with other cancer treatments. Data from this phase 1 study have prompted three additional ...

For the first time, scientists have identified promising drug candidates that bind irreversibly with a notoriously ...

No. 5 / 2025Zealand Pharma increases its share capital as a result of the exercise of employee warrantsCopenhagen, ...

For the first time scientists have identified promising drug candidates that bind irreversibly with a notoriously "undruggable" cancer protein target, permanently blocking it.

Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and ...

Researchers at the Icahn School of Medicine at Mount Sinai, led by Nina Bhardwaj, MD, Ph.D., Ward-Coleman Chair in Cancer ...

BRP emerges as a promising peptide for weight loss, activating appetite control pathways without triggering nausea, paving ...

Enrollment complete in Phase 2 Avail™ trial of canvuparatide in hypoparathyroidism; topline results on track for Q3 2025. MBX 1416 Phase 2 trial in patients with post-bariatric ...

Stanford Medicine researchers have identified a promising, naturally occurring molecule that could help people lose ...